top of page

Free Biopharma Daily Stock Updates - 07/14/21

$XBI $125.95 -2.80%


Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!


Covid Updates

$IBRX -4.6% ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19 source

Pipeline Updates

$TMDX +-0.0% TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Liver System source

$RIGL -1.5% New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress source

$GBIO -8.0% Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update source

$EVFM -1.40% Early Look at Second Quarter Metrics for Phexxi® Reveals Strong Growth source

$SESN 0.50% Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum source

$URGN +2.70% UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021 source

$JAGX -10.0% Jaguar Health Announces Completion of Investigator-Initiated Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients source

$ACRX +24.0% AcelRx Enters into Licensing Agreement for DZUVEO® in Europe and In-licensing Agreement for Two Products in the U.S. source

$MDNA +2.0% Medicenna’s IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer source

$ACAD -2.30% Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC) source

$HEPA -6.40% Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved source

$GLPG -1.80% Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation source

$GLPG -1.80% Galapagos reports positive topline results with selective TYK2 inhibitor

GLPG3667 in Phase 1b psoriasis study source

$SANA -1.70%Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates source

$AGLE +0.30% Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease source

$FGEN +1.0% FDA Briefing Document Cardiovascular and Renal Drugs Advisory Committee Meeting July 15, 2021 Roxadustat source

Financial Updates

$INMB -14.0% Inmune Bio, Inc. Announces $40 Million Registered Direct Offering source

$IMUX -3.50% Immunic, Inc. Announces Proposed Public Offering of Common Stock source

$IMV -3.3% IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Units source


Posted by JM

bottom of page